Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2019 May 21;14(2):54-61.
doi: 10.15420/icr.2019.5.1. eCollection 2019 May.

Update on the Current Landscape of Transcatheter Options for Tricuspid Regurgitation Treatment

Jonathan Curio  1   2 , Ozan M Demir  3 , Matteo Pagnesi  1 , Antonio Mangieri  4 , Francesco Giannini  4 , Giora Weisz  5 , Azeem Latib  5
Affiliations
Review

Update on the Current Landscape of Transcatheter Options for Tricuspid Regurgitation Treatment

Jonathan Curio et al. Interv Cardiol. .

Abstract

Most patients with severe tricuspid regurgitation lack treatment options because of prohibitive surgical risk. New transcatheter treatments under development and investigation might be able to address this unmet clinical need. This article gives an update on the landscape of devices for transcatheter tricuspid regurgitation treatment including different approaches (i.e. repair with leaflet approximation or annuloplasty and replacement using orthotopic or heterotopic valves) at different stages of development, from experimental to clinical trial. Repair devices such as the Cardioband or the MitraClip are leading the field with promising preliminary data and further trials are ongoing. However, with implantations of the Gate bioprosthesis, replacement devices are catching up. Potential advantages of different approaches and most recent data are discussed.

Keywords: Tricuspid regurgitation; annuloplasty; devices; repair; replacement; transcatheter; treatment options; tricuspid valve.

PubMed Disclaimer

Conflict of interest statement

Disclosure: AL is a consultant for Medtronic, Abbott Vascular, Mitralign and Millipede. All other authors have no conflicts of interest to declare.

Figures

Figure 1:
Figure 1:. Transcatheter Tricuspid Landscape
Figure 2:
Figure 2:. Different Stages of Tricuspid Regurgitation and Suitable Transcatheter Treatments
See this image and copyright information in PMC

References

    1. Singh JP, Evans JC, Levy D et al. Prevalence and clinical determinants of mitral, tricuspid, and aortic regurgitation (the Framingham Heart Study) Am J Cardiol. 1999;83:897–902. doi: 10.1016/S0002-9149(98)01064-9. - DOI - PubMed
    1. Topilsky Y, Maltais S, Medina Inojosa J et al. Burden of tricuspid regurgitation in patients diagnosed in the community setting. JACC Cardiovasc Imaging. 2019;12((3)):433–42. doi: 10.1016/j.jcmg.2018.06.014. - DOI - PubMed
    1. Nath J, Foster E, Heidenreich PA et al. Impact of tricuspid regurgitation on long-term survival. J Am Coll Cardiol. 2004;43:405–9. doi: 10.1016/j.jacc.2003.09.036. - DOI - PubMed
    1. Mangieri A, Montalto C, Pagnesi M et al. Mechanism and implications of the tricuspid regurgitation: from the pathophysiology to the current and future therapeutic options. Circ Cardiovasc Interv. 2017;10 doi: 10.1161/CIRCINTERVENTIONS.117.005043. - DOI - PubMed
    1. Ong K, Yu G, Jue J et al. Prevalence and spectrum of conditions associated with severe tricuspid regurgitation. Echocardiography. 2014;31:558–62. doi: 10.1111/echo.12420. - DOI - PubMed